IL15 and neoplasm: Moreover, the tumor engrafted HIS mice were used for a preclinical trial to test the potential of IL‐15 in combination with trastuzumab (anti‐HER2 mAb) therapy with the intention to enhance antibody‐dependent cellular cytotoxicity (ADCC; Wege et al, 2017).